Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma
- 1 November 2013
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 61 (4) , 601-605
Abstract
Background: Reporting ototoxicity is frequently complicated by use of various ototoxicity criteria. The International Society of Pediatric Oncology (SIOP) ototoxicity grading scale was recently proposed for standardized use in reporting hearing loss outcomes across institutions. The aim of this study was to evaluate the concordance between the Chang and SIOP ototoxicity grading scales. Differences between the two scales were identified and the implications these differences may have in the clinical setting were discussed.Procedures: Audiological evaluations were reviewed for 379 patients with newly diagnosed medulloblastoma (ages 3–21 years). Each patient was enrolled on one of two St. Jude clinical protocols that included craniospinal radiation therapy and four courses of 75 mg/m2 cisplatin chemotherapy. The latest audiogram conducted 5.5–24.5 months post‐protocol treatment initiation was graded using the Chang and SIOP ototoxicity criteria. Clinically significant hearing loss was defined as Chang grade ≥2a and SIOP ≥2. Hearing loss was considered serious (requiring a hearing aid) at the level of Chang grade ≥2b and SIOP ≥3.Results: A strong concordance was observed between the Chang and SIOP ototoxicity scales (Stuart's tau‐c statistic = 0.89, 95% CI: 0.86, 0.91). Among those patients diagnosed with serious hearing loss, the two scales were in good agreement. However, the scales deviated from one another in classifying patients with less serious or no hearing loss.Conclusions: Although discrepancies between the Chang and SIOP ototoxicity scales exist primarily for patients with no or minimal hearing loss, the scales share a strong concordance overall. Pediatr Blood Cancer 2014;61:601–605.Keywords
Funding Information
- National Cancer Institute Cancer Center CORE (CA 21765)
- Noyes Brain Tumor Foundation
- Musicians Against Childhood Cancer
- America Lebanese Syrian Associated Charities
This publication has 24 references indexed in Scilit:
- Clinically accurate assessment and grading of ototoxicityThe Laryngoscope, 2011
- Critical Need for International Consensus on Ototoxicity Assessment CriteriaJournal of Clinical Oncology, 2010
- Practical Grading System for Evaluating Cisplatin Ototoxicity in ChildrenJournal of Clinical Oncology, 2010
- Clinical Pharmacokinetics of Amifostine and WR1065 in Pediatric Patients with MedulloblastomaClinical Cancer Research, 2010
- Ototoxicity in children treated for osteosarcomaPediatric Blood & Cancer, 2009
- Amifostine Protects Against Cisplatin-Induced Ototoxicity in Children With Average-Risk MedulloblastomaJournal of Clinical Oncology, 2008
- Sensorineural Hearing Loss After Radiotherapy and Chemoradiotherapy: A Single, Blinded, Randomized StudyJournal of Clinical Oncology, 2006
- Ototoxicity in Children Receiving Platinum Chemotherapy: Underestimating a Commonly Occurring Toxicity That May Influence Academic and Social DevelopmentJournal of Clinical Oncology, 2005
- Predicting cisplatin ototoxicity in children: the influence of age and the cumulative doseEuropean Journal of Cancer, 2004
- High-Frequency Audiometric Monitoring Strategies for Early Detection of OtotoxicityEar & Hearing, 1994